Table 1: Population characteristics (Full Analysis Set).
| - |
- |
RA |
SpA |
Total |
| - |
n (missing) |
(N=309) |
(N=183) |
(N=492) |
| Age in years |
492 (0) |
59·0 (19·0 - 85·0) |
49·0 (19·0 - 87·0) |
55·5 (19·0 - 87·0) |
| Gender - percent female |
492 (0) |
221 (72%) |
90 (49%) |
311 (63%) |
| Duration of disease in years |
485 (7) |
7·0 (0·0 - 61·0) |
5·0 (0·0 - 46·0) |
6·0 (0·0 - 61·0) |
| Indication |
492 (0) |
- |
- |
- |
| Rheumatoid arthritis (RA) |
- |
.. |
.. |
309 (63%) |
| Psoriatic arthritis |
- |
.. |
.. |
88 (18%) |
| Axial spondyloarthritis |
- |
.. |
.. |
95 (19%) |
| Disease Activity Score |
- |
- |
- |
- |
| Rheumatoid arthritis DAS28 |
163 (146) |
3·0 (0·0 - 7·0) |
.. |
3·0 (0·0 - 7·0) |
| Psoriatic arthritis DAS28 |
44 (44) |
.. |
2·9 (1·0 - 7·0) |
2·9 (1·0 - 7·0) |
| Axial spondyloarthritis BASDAI |
71 (24) |
.. |
3·0 (0·0 - 9·0) |
3·0 (0·0 - 9·0) |
|
Type of previous therapya
|
492 (0) |
- |
- |
- |
| bDMARD |
- |
88 (28%) |
72 (39%) |
160 (33%) |
| csDMARD |
- |
255 (83%) |
83 (45%) |
338 (69%) |
| NSAID |
- |
106 (34%) |
96 (52%) |
202 (41%) |
| Glucocorticoids |
- |
213 (69%) |
43 (23%) |
256 (52%) |
| Previous bDMARD therapy |
492 (0) |
- |
- |
- |
| Naïve to bDMARDs |
- |
220 (71%) |
111 (61%) |
331 (67%) |
| Switch from injection to pen |
- |
37 (12%) |
22 (12%) |
59 (12%) |
| Switch from pen to pen |
- |
45 (15%) |
48 (26%) |
93 (19%) |
| Other bDMARD therapy (i.v.) |
- |
7 (2%) |
2 (1%) |
9 (2%) |
Data are n (%) or median (range). Percentages based on all non-missing subjects. a Multiple responses possible. RA=Rheumatoid Arthritis, SpA=Spondyloarthropathies, DAS=Disease Activity Score, BASDAI=Bath Ankylosing Spondylitis Disease Activity Index, DMARD=Disease-Modifying Antirheumatic Drug, b=Biological, cs=Conventional Synthetic, NSAID=Non-Steroidal Anti-Inflammatory Drug, i.v.= Intravenous Infusion